ArticleCureus2025
A Novel Predictor Compared to the Model for End-Stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP) Scores for Predicting 30-Day Mortality in Patients With Liver Cirrhosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A New Nomogram for Mortality Prediction Within 5 Years in Portal Vein Thrombosis due to Hepatitis B-Related Cirrhosis.Journal of viral hepatitis · 2026Article
- The Prognostic Value of Biomarkers in Patients Diagnosed with Spontaneous Bacterial Peritonitis.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Liver cirrhosis (LC) is characterized by the development of fibrosis and nodules within the liver, leading to progressive liver dysfunction. The mortality rate associated with LC has consistently remained high over the years. Prognostic tools such as the Child-Turcotte-Pugh (CTP) score and the Model for End-Stage Liver Disease (MELD) score are commonly used to predict mortality and assess the severity of LC. Both scoring systems rely on laboratory parameters, including serum albumin, total bilirubin, and international normalized ratio (INR) levels. However, the CTP score interpretation can be variable, and INR testing is not routinely performed in many clinical settings, which may limit its utility. This study aims to assess the MELD and CTP scores, along with a new predictive tool, in estimating 30-day mortality for patients with LC. Methodology This retrospective cohort study focuses on patients diagnosed with LC at Ngoerah Central General Hospital. Physical examination data and laboratory ratios, including neutrophil-to-lymphocyte ratio (NLR), aspartate transaminase (AST) to alanine transaminase (ALT) ratio (de Ritis), neutrophil-to-lymphocyte-to-albumin (NLA) ratio, albumin bilirubin index (ALBI), and blood urea nitrogen-to-albumin ratio (BAR), were collected from medical records. Optimal cutoff values were established using receiver operating characteristic (ROC) curves. Survival analysis was performed using the Kaplan-Meier method, and multivariate Cox regression was employed to determine the hazard ratio (HR) for each variable that was statistically significant as a predictor of 30-day mortality. Results In this study, a total of 140 samples were analyzed. Kaplan-Meier analysis revealed that hepatic encephalopathy (HE) met the criteria, while interaction analysis testing was required for other variables. Results from the multivariate Cox regression interaction model showed that ALBI-HE (HR = 1.743, 95% confidence interval [CI] 1.102-2.759,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.